biochemical recurrence

February 10, 2021February 10, 2021

New AI Tool May Better Predict Relapse After Surgery

News

Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called ... Read more

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. “The ... Read more

May 13, 2019

Evidence Supports Stereotactic Body Radiotherapy as a Standard of Care for Localized PC

News

Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods of time — as a standard treatment for people ... Read more

December 6, 2018

New Imaging Agent Better at Detecting Signs of Prostate Cancer Recurrence, Study Reports

News

A new imaging agent for use in positron emission tomography (PET) is better than conventional imaging at detecting cancer location and spread in prostate cancer patients suspected of cancer recurrence, ... Read more

November 21, 2018

Radiation Treatments Delay Metastasis, Recurrence in Aggressive Prostate Cancers

News

Radiation therapy approaches — including external beam radiation therapy (EBRT) and brachytherapy — for prostate cancer patients with aggressive disease are better at extending the time to metastasis or cancer ... Read more

February 21, 2018February 21, 2018

Prostate Imaging Scans Using 68Ga-PSMA-11 Recommended by UCLA Researchers

News

Prostate cancer patients who have disease recurrence following radical prostatectomy should undergo imaging scans using the imaging agent 68Ga-PSMA-11 to guide their salvage radiotherapy, a new study suggests. The study, by ... Read more

February 5, 2018

Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine

News

Panacea Pharmaceuticals has completed patient enrollment in a Phase 1 clinical trial testing its PAN-301-1 vaccine as a treatment for prostate cancer that has failed to respond to other therapies. The multi-center trial (NCT03120832) ... Read more

October 2, 2017October 2, 2017

Axumin PET/CT Scans in Men with Suspected Recurrent Prostate Cancer May Change Treatment Plans

News

More than six out of 10 men whose doctors suspected their prostate cancer had returned due to rising prostate specific antigen (PSA) levels saw their treatment plans revised after being ... Read more